166 related articles for article (PubMed ID: 21618420)
21. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T
Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
[TBL] [Abstract][Full Text] [Related]
22. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.
Gaynon PS; Bostrom BC; Hutchinson RJ; Lange BJ; Nachman JB; Steinherz PG; Sensel MG; Lee MK; Stram DO; Sather HN
J Clin Oncol; 2001 Apr; 19(7):1916-25. PubMed ID: 11283123
[TBL] [Abstract][Full Text] [Related]
23. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
25. Cost of childhood acute lymphoblastic leukemia care in Shanghai, China.
Liu Y; Chen J; Tang J; Ni S; Xue H; Pan C
Pediatr Blood Cancer; 2009 Oct; 53(4):557-62. PubMed ID: 19526524
[TBL] [Abstract][Full Text] [Related]
26. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
[TBL] [Abstract][Full Text] [Related]
27. A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.
Kloos RQH; van Litsenburg RRL; Wolf S; Wismans L; Kaspers GJL; Uyl-de Groot CA; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2019 Jan; 66(1):e27458. PubMed ID: 30246496
[TBL] [Abstract][Full Text] [Related]
28. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
Koperna T; Semmler D
Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
[TBL] [Abstract][Full Text] [Related]
29. Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Tong WH; van der Sluis IM; Alleman CJ; van Litsenburg RR; Kaspers GJ; Pieters R; Uyl-de Groot CA
Haematologica; 2013 May; 98(5):753-9. PubMed ID: 23403311
[TBL] [Abstract][Full Text] [Related]
30. Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
Gupta S; Sutradhar R; Li Q; Athale U; Bassal M; Breakey V; Gibson PJ; Patel S; Silva M; Zabih V; Pechlivanoglou P; Pole JD; Mittmann N
Eur J Cancer; 2021 Jul; 151():126-135. PubMed ID: 33979728
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood.
Rae C; Furlong W; Jankovic M; Moghrabi A; Naqvi A; Sala A; Samson Y; DePauw S; Feeny D; Barr R
Eur J Cancer Care (Engl); 2014 Nov; 23(6):779-85. PubMed ID: 24393150
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia.
Yu YB; Gau JP; You JY; Chern HH; Chau WK; Tzeng CH; Ho CH; Hsu HC
Ann Oncol; 2007 Mar; 18(3):529-34. PubMed ID: 17164232
[TBL] [Abstract][Full Text] [Related]
33. Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91.
von Stackelberg A; Karatchunsky A; Kudrjashova J; Miakova N; Belikova L; Rumiantzev A; Hartmann R; Henze G
Eur J Cancer; 1999 Sep; 35(9):1349-55. PubMed ID: 10658526
[TBL] [Abstract][Full Text] [Related]
34. A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
Kloos RQH; Uyl-de Groot CA; van Litsenburg RRL; Kaspers GJL; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28766887
[TBL] [Abstract][Full Text] [Related]
35. Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols.
Rahiala J; Riikonen P; Kekäläinen L; Perkkiö M
Acta Paediatr; 2000 Apr; 89(4):482-7. PubMed ID: 10830464
[TBL] [Abstract][Full Text] [Related]
36. Levofloxacin prophylaxis in hospitalized children with leukemia: A cost-utility analysis.
Maser B; Pelland-Marcotte MC; Alexander S; Sung L; Gupta S
Pediatr Blood Cancer; 2020 Oct; 67(10):e28643. PubMed ID: 32785971
[TBL] [Abstract][Full Text] [Related]
37. Comparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.
Mungle T; Das N; Pal S; Gogoi MP; Das P; Ghara N; Ghosh D; Arora RS; Bhakta N; Saha V; Krishnan S
Cancer Med; 2023 Feb; 12(3):3499-3508. PubMed ID: 36812120
[TBL] [Abstract][Full Text] [Related]
38. Upfront Treatment Influences the Composition of Genetic Alterations in Relapsed Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Yu J; Waanders E; van Reijmersdal SV; Antić Ž; van Bosbeek CM; Sonneveld E; de Groot H; Fiocco M; Geurts van Kessel A; van Leeuwen FN; Pieters R; Hoogerbrugge PM; Kuiper RP
Hemasphere; 2020 Feb; 4(1):e318. PubMed ID: 32072138
[TBL] [Abstract][Full Text] [Related]
39. Childhood acute lymphoblastic leukemia in India: an approach to management in a three-tier society.
Chandy M
Med Pediatr Oncol; 1995 Sep; 25(3):197-203. PubMed ID: 7623729
[TBL] [Abstract][Full Text] [Related]
40. Childhood cancer--mainly curable so where next?
Craft AW
Acta Paediatr; 2000 Apr; 89(4):386-92. PubMed ID: 10830445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
